TSC Staff
Meanwhile, Genzyme (GENZ Quote - Cramer on GENZ - Stock Picks) and Isis (ISIS Quote - Cramer on ISIS - Stock Picks) said FDA requirements will result in some delays for Mipomersen, the cholesterol-lowering antisense drug at the heart of their joint venture deal announced in January. The news sent Isis shares down $4.83, or 28.8%, to $11.97. Genzyme shares were down 88 cents, or 1.2%, to $72.46.
And finally, in analyst action: Credit Suisse analyst Ken Weakley upgraded health-care services company Tenet Healthcare (THC Quote - Cramer on THC - Stock Picks) on Friday to outperform from neutral, raising his price target to $8 from $6, with optimism for price -- and subsequently revenue -- improvement. Shares were up 71 cents, or 13%, at $6.17.
Featured Photo Galleries
Sign up for our FREE newsletters now.
See All
Sponsored by:
RSS
